APPROVED_FOR_MARKETINGNot Applicable

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

United States

Plain-language summary

This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or satisfactory alternative therapy for treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent.
✓. Male or female patient at least 18 years old.
✓. Clinical diagnosis active TED with a CAS ≥ 4 (on the 7-item scale).
✓. Moderate-to-severe active TED (not sight-threatening but has an appreciable impact on daily life), usually associated with one or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement, exophthalmos ≥ 3 mm above normal for race and gender, and/or inconstant or constant diplopia.
✓. Onset of Active TED symptoms (as determined by patient records) within approximately 12 months prior to eligibility review.
✓. Patients must be euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \[FT4\] and free triiodothyronine \[FT3\] levels \< 50% above or below the normal limits) at Eligibility review. Every effort should be made to correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the full duration of participation.
✓. Does not require immediate surgical ophthalmological intervention.
✓. Diabetic patients must have well-controlled stable disease (defined as HbA1c \< 9.0%).

Exclusion criteria

✕. Any treatment with rituximab (Rituxan® or MabThera®) within 12 months prior to the first infusion of teprotumumab or tocilizumab (Actemra® or Roactemra®) within 6 months prior to the first infusion of teprotumumab. Use of any other non-steroid immunosuppressive agent within 3 months prior to the first infusion of teprotumumab.
✕. Use of an investigational agent for any condition within 60 days prior to the first infusion or anticipated use during the course of the protocol.
✕. Pregnant or lactating women.
✕. Biopsy-proven or clinically suspected IBD (e.g., diarrhea with or without blood or rectal bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or incontinence for more than 4 weeks without a confirmed alternative diagnosis OR endoscopic or radiologic evidence of enteritis/colitis without a confirmed alternative diagnosis).
✕. Known hypersensitivity to any of the components of teprotumumab or prior hypersensitivity reactions to mAbs.
✕. Any other condition that, in the opinion of the Sponsor, would preclude inclusion in the expanded access program.
✕. Previous enrollment in this study or participation in a prior teprotumumab clinical study.
✕. Human immunodeficiency virus, hepatitis C or hepatitis B infections.

Trial details

NCT IDNCT04040894

SponsorAmgen

Sponsor typeINDUSTRY

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Thyroid Eye Disease trials